![]() Breast cancer MDA-MB-231 and MCF-7 cell lines or non-malignant cells (HEK293T, HMEC, MCF-10A, or BM-MSC) were used as targets to assess the reactivity or cytotoxic activity of the PD-L1-CAR-bearing immune effector cells. New atezolizumab-based PD-L1-targeted CAR was generated and introduced into T, NK, or NK-92 cells. Our study provides new information on the efficacy of such an approach against PD-L1 low targets. Recently, combining these approaches into a strategy of PD-L1-targeted CAR has been proposed to target PD-L1 high tumors. Immune checkpoint inhibitors and chimeric antigen receptor (CAR)-based therapies have transformed cancer treatment. 12 Department of Immunology, Medical University of Warsaw, Warszawa, Poland 13 Department of Clinical Immunology, Medical University of Warsaw, Warszawa, Mazowieckie, Poland 14 Department of Regenerative Medicine, The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.11 Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway.10 Department of Cancer Immunology, Radiumhospitalet, Oslo, Norway.9 Department of Bioinformatics, Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland.8 Doctoral School of Translational Medicine, Centre of Postgraduate Medical Education, Warsaw, Poland. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |